The co-occurrence of alterations in EGFR, MET, HER3, CCNE1, CDK6, CCND1 and PIK3CA in HER2-positive gastric carcinoma has been shown to confer resistance to HER2-targeted therapies in vitro [9]. Here, ERBB2 is linked to gastric carcinoma.